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Abstract
Background: We have recently synthesized novel N-alkylated amino acid-derived hydroxamate, 2-[Benzyl-(2-nitro-
benzenesulfonyl)-amino]-N-hydroxy-3-methyl-N-propyl-butyramide (NAHA). Here, we evaluate the anticancer activity of
NAHA against highly invasive human breast cancer cells MDA-MB-231 in vitro and in vivo.
Methodology/Principal Findings: Cell growth was evaluated by MTT and soft agar assays. Protein expression was
determined by DNA microarray and Western blot analysis. Metastatic potential was evaluated by cell adhesion, migration,
invasion, capillary morphogenesis, and ELISA assays. The anticancer activity in vivo was evaluated in mouse xenograft
model. NAHA inhibited proliferation and colony formation of MDA-MB-231 cells together with the down-regulation of
expression of Cdk2 and CDC20 proteins. NAHA inhibited cell adhesion, migration, and invasion through the suppression of
secretion of uPA. NAHA suppressed secretion of VEGF from MDA-MB-231 cells and inhibited capillary morphogenesis of
human aortic endothelial cells (HAECs). Finally, NAHA at 50 mg/kg was not toxic and decreased tumor volume and tumor
weight in vivo. This suppression of tumor growth was associated with the inhibition of mitotic figures and induction of
apoptosis, and the reduction of CD31 and VEGF positive cells in tumors.
Conclusion: NAHA could be a novel promising compound for the development of new drugs for the therapy of invasive
breast cancers.
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Introduction
Hydroxamic acids are able to chelate metal ions and therefore
inhibit metal-containing enzymes such as matrix metalloprotei-
nases (MMPs) [1]. Overexpression of MMPs has been linked to a
variety of diseases including cancer, rheumatoid arthritis,
osteoarthritis and cardiovascular disease [2,3]. Despite the
promising preclinical studies with synthetic hydroxamate-based
MMP inhibitors, these inhibitors were not specific only for MMPs
and most importantly, clinical studies revealed severe adverse side-
effect such as the musculoskeletal syndrome [3,4]. Therefore, the
development of selectively specific MMP inhibitors without their
side effects is necessary for the clinical studies [5]. However,
certain chemical modifications in the structure of hydroxamic
acids, such as N-alkylation, eliminated their MMP inhibitory
activity [6,7,8]. We have recently synthesized a small library of N-
alkylated amino acid-derived sulfonamide hydroxamates, and
identified 2-[Benzyl-(2-nitro-benzenesulfonyl)-amino]-N-hydroxy-3-meth-
yl-N-propyl-butyramide (NAHA) as the most potent inhibitor of
proliferation of highly invasive human breast cancer cells [9].
Breast cancer is the leading cause of cancer death in women
worldwide [10]. One of the reasons for such a high mortality is
invasive behavior of breast cancer cells. Therefore, breast cancer
often progresses from the nonmetastatic and therapy-responsive
phenotype to the highly invasive and metastatic phenotype, which
is usually resistant to standard therapeutic procedures [11,12].
Cancer metastasis consist from several interdependent processes
including uncontrolled growth of cancer cells, their invasion
through surrounding tissues, migration to the distant sites of the
human body, and adhesion, invasion and colonization of other
organs and tissues [13]. In addition, tumor growth and metastasis
also require angiogenesis, the formation of blood vessels by
capillaries sprouting from pre-existing vessels [14]. Therefore,
suppression of growth and invasiveness of cancer cells, and cancer
cells mediated angiogenesis could lead to the inhibition of cancer
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e34283metastasis and would eventually further increase survival of breast
cancer patients.
In the present study, we evaluated the effect of NAHA on highly
invasive MDA-MB-231 cells representing metastatic human breast
cancer cells. Here, we show that NAHA inhibits cell proliferation
(anchorage-dependent growth) as well as colony formation
(anchorage-independent cell growth) of MDA-MB-231 cells. In
addition, NAHA inhibits invasive behavior (cell adhesion,
migration and invasion) of breast cancer cells, and suppresses
breast cancer cell-mediated angiogenesis of vascular endothelial
cells in vitro. Finally, NAHA inhibits tumor growth and
angiogenesis in a xenograft model of breast cancer. Collectively,
our study suggests newly synthesized derivative of hydroxamic acid
(NAHA) for the treatment of breast cancer.
Results
Effect of NAHA on the proliferation and colony formation
of highly invasive breast cancer cells
We have recently synthesized and identified N-alkylated amino
acid-derived sulfonamide hydroxamate, NAHA (Figure 1A), which
inhibited growth of human breast cancer cells at IC50 30 mM [9].
To compare the effect of NAHA on highly invasive (MDA-MB-
231), poorly invasive (MCF-7) breast cancer cells, and human
mammary epithelial cells (MCF-10A) and primary human
mammary epithelial cells (HMECs) we treated these cells with
NAHA (0–50 mM) for 24 hours and the proliferation and cell
viability were determined. Interestingly, NAHA inhibited prolif-
eration of all tested cells but the inhibition of cell proliferation was
not associated with cell viability (Figure 1B–E). Therefore, NAHA
at 50 mM suppressed proliferation of MDA-MB-231 by 84%
(Figure 1B), MCF-7 by 58% (Figure 1C), MCF-10A by 72%
(Figure 1D) and HMECs by 70% (Figure 1E) suggesting that the
most sensitive to NAHA are highly invasive breast cancer cells
MDA-MB-231.
Cancer cells can growth under the nonadhesive condition and
this anchorage-independent growth (colony formation) is correlat-
ed with in vivo oncogenic potential of cancer cells. Because colony
formation is a key parameter for cells to acquire a metastatic
potential [15], we evaluated effects of NAHA on colony formation
of highly invasive MDA-MB-231 cells. In agreement with cell
proliferation, NAHA decreased the number of colonies of MDA-
MB-231 cells (Figure 1F). These results suggest that NAHA
inhibited the anchorage-dependent (cell proliferation) as well as
anchorage-independent (colony formation) growth of invasive
breast cancer cells.
Effect of NAHA on the expression of cell cycle regulatory
proteins
Since NAHA suppressed growth of breast cancer cells, we were
interested which of the cell cycle regulatory proteins could be
potential targets for this compound. MDA-MB-231 cells were
treated with NAHA (0, 25, 50 mM) for 24 hours, RNA was
extracted and the expression of cell cycle regulatory genes was
evaluated by Cycle Oligo GEArray. Our data demonstrate that
NAHA at the concentration 50 mM markedly down-regulated
mRNA levels of several genes, including ANAPC4 (ratio to control
0.53), ANAPC5 (0.58), cyclin B1 (0.61), cyclin H (0.53), CDC20 (0.68),
CDC25C (0.80), Cdk2 (0.70), Ki 67 (0.55), CKS1B (0.57), CKS2
(0.65), culin 1 (0.47), E2F1 (0.70), MCM2 (0.66), TFDP1 (0.68), and
survivin (0.82) in MDA-MB-231 cells. To confirm that NAHA
regulates expression of these genes on the protein level, MDA-MB-
231 cells were treated with NAHA (0–50 mM) for 24 hours, whole
cell extracts prepared and subjected to Western blot analysis.
Although the expression of some proteins, e.g. cyclin-B1 or PCNA,
was down-regulated only marginally (not shown), NAHA mark-
edly suppressed expression of cyclin-dependent kinase 2 (Cdk2)
and cell division cycle 20 (CDC20) proteins, respectively
(Figure 1G).
Effect of NAHA on invasive behavior of breast cancer
cells
In addition to the uncontrolled proliferation and colony
formation, cancer metastasis depends on adhesion, migration
and invasion of cancer cells. Breast cancer cells express integrin
receptor aVb3, which through its interaction with an extracellular
matrix (ECM) protein vitronectin, contributes to the cancer cell
adhesion and migration [16]. To evaluate whether NAHA inhibits
adhesion of breast cancer cells, MDA-MB-231 cells were treated
with NAHA (0–50 mM) for 24 hours and their adhesion to
vitronectin was determined. As seen in Figure 2A, NAHA
markedly suppressed adhesion of MDA-MB-231 cells to extracel-
lular matrix protein vitronectin. Further, we evaluated if NAHA
directly inhibits cell migration. MDA-MB-231 cells were pretreat-
ed with NAHA (0–50 mM) for 1 h and cell migration was
determined after additional 4 hours of incubation. As seen in
Figure 2B, NAHA also significantly decreased migratory potential
of breast cancer cells in a dose dependent-manner. Finally, we
evaluated the effect of NAHA on cell invasiveness. MDA-MB-231
cells were plated on the Matrigel-coated filters in the presence of
NAHA (0–50 mM) and the amount of cells invaded through
Matrigel counted after 24 hours of incubation. As seen in
Figure 2C, NAHA also inhibits invasion of MDA-MB-231 cells.
Cancer metastasis and invasiveness is associated with the
expression of serine protease, urokinase-type plasminogen activa-
tor (uPA) which overexpression was reported in various human
malignant cancers and was linked to advanced tumors and
decreased survival time [17]. Therefore, we evaluated whether the
inhibition of invasive behavior of breast cancer cells by NAHA
could be mediated by the suppression of uPA secretion. MDA-
MB-231 cells were treated with NAHA (0–50 mM) for 24 hours
and the expression of uPA was determined in cell conditioned
medium by Western blot analysis. As seen in Figure 2D, NAHA
markedly reduced the secretion of uPA from MDA-MB-231 cells
suggesting that NAHA inhibits invasiveness of breast cancer cells
by the down-regulation of expression of uPA.
Effect of NAHA on capillary morphogenesis of
endothelial cells
Cancer progression and metastasis is also linked to the
angiogenesis, which can be (on the cellular level) characterized
by the tube formation (capillary morphogenesis) of endothelial
cells. Indeed, we have recently demonstrated that highly invasive
breast cancer cells MDA-MB-231 secrete vascular endothelial
growth factor (VEGF) which stimulated capillary morphogenesis
of endothelial cells [18]. To determine the effect of NAHA on the
secretion of VEGF, MDA-MB-231 cells were treated with NAHA
(0–50 mM) for 24 hours, cell culture media (conditioned media)
collected and VEGF levels evaluated by ELISA as described in
Materials and Methods. As seen in Figure 2E, NAHA markedly
suppressed secretion of VEGF from MDA-MB-231 cells into
media. Next, we determined whether NAHA suppresses capillary
morphogenesis of human epithelial aortic cells (HAECs). There-
fore, HAECs grown on Matrigel were treated with NAHA (0–
50 mM) for 24 hours, and tube formation were evaluated. As seen
in Figure 2F, NAHA suppressed capillary morphogenesis of
HAEC cells in a dose-response manner. Collectively, our data
N-alkyl-hydroxamate Inhibits Breast Cancer
PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e34283Figure 1. NAHA inhibits growth of breast cancer cells. (A) Structure of NAHA, 2-[Benzyl-(2-nitro-benzenesulfonyl)-amino]-N-hydroxy-3-methyl-N-
propyl-butyramide. (B) MDA-MB-231, (C) MCF-7, (D) MCF-10A, (E) HMEC cells were treated with NAHA (0–50 mM). Cell proliferation was determined by
the tetrazolium salt method as described in Materials and Methods. Cell viability was determined by trypan blue staining as described in Materials and
Methods. Data are the means 6 SD. Similar results were obtained in at least two additional experiments. * p,0.05 for cell proliferation, # p,0.05 for
cell viability. (F) Anchorage-independent growth (colony formation) of MDA-MB-231 cells was assessed on 1% agarose after incubation with NAHA (a
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PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e34283–0 ,b–1 0mM, c -25 mM, d – 50 mM) for 14 days as described in Materials and Methods. (G) MDA-MB-231 cells were treated with NAHA (0–50 mM) for
24 hours and whole cell extracts were subjected to Western blot analysis with anti-Cdk2 and anti-CDC20 antibodies as described in Materials and
Methods. The equal protein loading was verified with anti b-actin antibodies. The rfesults are representative of three independent experiments.
doi:10.1371/journal.pone.0034283.g001
Figure 2. NAHA inhibits invasive behavior of breast cancer cells and capillary morphogenesis of endothelial cells. (A) Cell adhesion.
MDA-MB-231 cells were treated with NAHA (0–50 mM) for 24 hours and cell adhesion to vitronectin determined as described in Materials and
Methods. Each bar represents the mean 6 SD of three experiments. * p,0.05. (B) Cell migration. Cell migration of MDA-MB-231 cells was determined
after 5 hours of incubation in the presence of NAHA (0–50 mM), as described in Materials and Methods. Each bar represents the mean 6 SD of three
experiments. * p,0.05. (C) Cell invasion. Invasion of MDA-MB-231 cells through Matrigel was determined after 24 hours of incubation in the presence
of NAHA (0–50 mM) as described in Materials and Methods. Each bar represents the mean 6 SD of three experiments. * p,0.05. (D) uPA secretion.
MDA-MB-231 cells were treated with NAHA (0–50 mM) for 24 hours, and the expression of uPA detected in conditioned media from the same amount
of cells with anti-uPA antibody by Western blot analysis as described in Materials and Methods. The results are representative of three independent
experiments. (E) MDA-MB-231 cells were treated with NAHA (0–50 mM) for 24 hours, media collected and secretion of VEGF determined as described
in Materials and Methods. Each bar represents the mean 6 SD of three experiments. * p,0.05. (F) HAECs were treated with NAHA (0–50 mM) for
16 hours. Capillary morphogenesis was determined as described in Materials and Methods. Each bar represents the mean 6 SD of three experiments.
*p ,0.05.
doi:10.1371/journal.pone.0034283.g002
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cells and this effect is mediated through the suppression of
secretion of VEGF from breast cancer cells.
Effect of NAHA on tumor growth in vivo
To evaluate the effect of NAHA in vivo we employed a xenograft
model of human breast cancer cells MDA-MB-231 subcutaneosly
implanted into nude mice as described in Materials and Methods.
Intraperitoneal administration of NAHA (50 mg NAHA/kg of
body weight/3 times per week) for 32 days significantly suppressed
tumor volume in nude mice (Figure 3A). In addition, NAHA
treatment significantly suppressed final tumor weight (Figure 3B).
Moreover, we did not observe any side effect of NAHA and there
were no differences in body weight between control and treatment
groups (Figure 3C), suggesting that NAHA is not toxic. In
addition, we did not observe any pathological changes in the liver,
spleen, kidney, lung and heart in NAHA treated animals. The
H&E staining revealed that suppression of growth by NAHA is
mediated by the slight inhibition of proliferation as demonstrated
by the decreased mitotic figures (Figures 4A and B) and significant
increase of apoptotic bodies in breast cancer xenografts (Figures 4A
and C). In addition, NAHA also suppressed angiogenesis in vivo as
demonstrated by significant decrease of CD31 (Figure 5A) and
VEGF (Figure 5B) positive cells in tumors from animals treated
with NAHA. In summary, NAHA suppresses growth of breast
cancer xenografts through the inhibition of proliferation, induction
of apoptosis and suppression of angiogenesis.
Discussion
In the present study we evaluated the effect of newly synthesized
derivate of hydroxamic acid, 2-[Benzyl-(2-nitro-benzenesulfonyl)-
amino]-N-hydroxy-3-methyl-N-propyl-butyramide (NAHA), on the
growth, angiogenesis and invasive behavior of breast cancer cells.
Here we show that NAHA markedly suppressed cancer cell
proliferation (anchorage-dependent growth), cancer cell colony
formation (anchorage-independent growth), invasive behavior of
cancer cells (cell adhesion, migration and invasion) and capillary
morphogenesis of endothelial cells. Moreover, we demonstrate
that NAHA inhibits tumor growth and angiogenesis in xenograft
model of human breast cancer.
Although NAHA inhibits proliferation of breast cancer as well
as normal mammary cells, this effect is cytostatic because cell
viability is affected only marginally in all tested cells. Moreover,
the suppressive effect of NAHA on cell proliferation was
prominent on the highly invasive breast cancer cells. Furthermore,
the DNA microarray analysis revealed that NAHA down-regulates
expression of several genes on mRNA levels, from which the
down-regulation of expression of Cdk2 and CDC20 was also
confirmed on the protein level. CDC20 is a protein regulating
spindle checkpoint controlling the mitotic chromosome segrega-
tion during cell proliferation, which has been recently suggested as
a potential therapeutic target [19,20]. Indeed, the overexpression
of CDC20 was demonstrated in breast cancer cell lines and
primary breast tumors but not in normal mammary epithelial cells
or breast tissues [19,21,22]. Therefore, NAHA suppresses growth
of breast cancer cells through the down-regulation of expression of
CDC20.
Cell invasion is the result of the activity of proteolytic enzymes
such as MMPs, cysteine proteases, and uPA [23,24,25]. Because
N-alkylation of hydroxamic acids eliminates their MMP inhibitory
activity [6,7,8], our data suggest that N-alkylated NAHA inhibited
cell invasion through the different mechanism, the suppression of
secretion of uPA from breast cancer cells. In addition, we and
others have previously reported that inhibition of uPA suppressed
invasion of breast cancer cells [26,27,28]. Inhibition of cell
adhesion and cell migration by NAHA can be mediated through
the uPA-uPAR receptor signaling independently of uPA activity,
because secreted uPA binds to uPAR and forms a complex with
integrin receptor aVb3, which is ligated to vitronectin [29]. In
addition, integrin receptor aVb3 is involved inf adhesion and
migration of breast cancer cells [16]. Therefore, inhibition of uPA
secretion by NAHA will suppress the formation of uPA-uPAR-
aVb3-vitronectin complex, resulting in the inhibition of adhesion
and motility of MDA-MB-231 cells.
Here, we show that NAHA suppresses secretion of VEGF from
MDA-MB-231 and inhibits capillary morphogenesis (tube forma-
tion) of endothelial cells. We have previously demonstrated that
the secretion of VEGF from MDA-MB-231 induces tube
formation of vascular endothelial cells, whereas the inhibition of
VEGF secretion suppresses this pro-angiogenic effect [18].
Moreover, suppression of endothelial capillary morphogenesis
through the inhibition of secreted VEGF from a variety of cancer
cells is well documented [30,31,32,33]. In addition to the
inhibition of cancer growth and invasive behavior of cancer cells,
NAHA suppresses one of the first steps in angiogenesis – capillary
morphogenesis of endothelial cells, and could therefore contribute
to the inhibition of tumor angiogenesis.
In addition to its in vitro activity, NAHA suppresses tumor
growth in a xenograft model of human breast cancer cells and this
effect is associated with decreased proliferation and induced
apoptosis of cancer cells. Moreover, NAHA also suppresses
angiogenesis of breast tumors and down-regulates expression of
VEGF in tumors in vivo.
In conclusion, NAHA, the N-alkyl derivate of hydroxamic acid,
is a novel promising anti-cancer and anti-angiogenic compound.
Therefore, it is possible to expect that the compounds based on the
structure of NAHA will not exhibit detrimental effects of the
previous hydroxamate-based MMP inhibitors. Further studies are
warranted to synthesize more potent NAHA analogs, to develop
specific targeted delivery to cancer cells, and to evaluate their
effects on breast cancer growth and metastasis in vivo.
Materials and Methods
Reagents
Synthesis and analysis of 2-[Benzyl-(2-nitro-benzenesulfonyl)-amino]-
N-hydroxy-3-methyl-N-propyl-butyramide (NAHA) were previously
described [9]. DMSO was purchased from Sigma (St. Louis,
MO, USA). NAHA was dissolved in DMSO at a concentration of
50 mM and stored at 220uC.
Cell culture
Primary human mammary epithelial cells (HMECs) were
obtained from Lonza (Walkersville, MD) and grown in Mammary
Epithelial Cell Growth Medium (MEGM, Lonza) with supple-
ments according to manufacturer’s protocol. Non-tumorigenic
MCF-10A human mammary epithelial cells and human breast
cancer cells MCF-7 and MDA-MB-231 were obtained from
ATCC (Manassas, VA). MCF-10A cells were maintained in
DMEM/F12 medium containing 5% horse serum (HS), insulin
(10 mg/ml), epidermal growth factor (EGF, 20 ng/ml), cholera
toxin (100 mg/ml), hydrocortisone (0.5 mg/ml), penicillin (50 U/
ml), and streptomycin (50 U/ml). MCF-7 and MDA-MB-231 cells
were maintained in DMEM medium containing penicillin (50 U/
ml), streptomycin (50 U/ml), and 10% fetal bovine serum (FBS).
Media and supplements came from Invitrogen (Grand Island, NY,
USA). HS and FBS were obtained from Hyclone (Logan, UT,
N-alkyl-hydroxamate Inhibits Breast Cancer
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from Clonetics (Walkersville, MD, USA) and maintained in
MEBM medium supplemented with EGMH-2 MV SingleQuots
kit and 1% antibiotic-antimycotic solution (1006). HAECs were
maintained at 37uC in a humidified atmosphere in the presence of
5% CO2. The cells were not used for more than 12 passages in
our experiments. MEBM complete medium, and EGMH-2 MV
SingleQuots kits were purchased from Clonetics.
Cell proliferation, cell viability and colony formation
Proliferation and cell viability of HMECs, MCF-10A, MCF-7
and MDA-MB-231 cells treated with NAHA (0–50 mM) for
24 hours was determined as we previously described [17,18].
Colony formation of MDA-MB-231 cells incubated in the
presence of NAHA (0–50 mM) was evaluated as described [34].
Data points represent mean 6 SD in one experiment repeated at
least twice.
DNA microarrays
MDA-MB-231 cells were treated with NAHA (0, 25, 50 mM) for
24 hours and total RNA isolated with RNAeasy (Qiagen,
Valencia, CA, USA). This RNA was used for the evaluation of
cell cycle regulatory genes with Cell Cycle Oligo GEArray
according to the manufacturer’s protocol (SA Biosciences,
Frederick, MD, USA).
Western blot analysis
MDA-MB-231 cells were treated with NAHA (0–50 mM) for
24 hours and whole cell extracts prepared as previously described
[35]. Equal amounts of proteins (20 mg/lane) were separated on
Figure 3. NAHA inhibits growth of breast cancer cells in vivo. (A) Tumor volume. MDA-MB-231 cells were inoculated s.c. in the right flank of
each mouse. Seven days after inoculation, mice were randomly divided into 3 groups (n=10) and treated with NAHA (i.p., 10 mg or 50 mg/kg of
body weight/3 times per week) or vehicle (n=11) for 32 days. Tumor volume was measured three times a week. Data are mean 6 SD, * significantly
different from control (p,0.05) using a two-sample Student t-test. (B) Tumor weight, * p,0.05. (C) Body weight of mice.
doi:10.1371/journal.pone.0034283.g003
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and transferred to a PVDF membrane (Millipore, Bedford, MA,
USA). The protein expression was detected with the correspond-
ing primary antibodies: anti-CDC20, anti-Cdk2, anti-cyclin-B1,
anti-PCNA, and anti-b-actin, (Santa Cruz Biotechnology, Santa
Cruz, CA, USA). Protein expression was visualized using the ECL
Western Blotting Detection System (Amersham Biosciences,
Buckinghamshire, UK).
Cell invasiveness
Cell adhesion of MDA-MB-231 cells treated with NAHA (0–
50 mM) for 24 hours was performed, as we described [36]. Cell
migration of MDA-MB-231 cells treated with NAHA (0–50 mM)
for 5 hours was evaluated, as previously described [35,36]. Cell
invasion of MDA-MB-231 cells treated with NAHA (0–50 mM) for
24 hours was performed as we described [36]. Data points
represent the mean 6 SD of three individual filters within one
representative experiment repeated at least twice.
uPA secretion
uPA secretion from MDA-MB-231 cells treated with NAHA (0–
50 mM) for 24 hours was evaluated as we previously described
[35]. The loading was normalized to the same amount of treated
cells.
Secretion of VEGF
MDA-MB-231 cells were treated with NAHA (0–50 mM) for
24 hours, cell media collected and secretion of VEGF was
determined by ELISA kit (R&D Systems, Minneapolis, MN,
USA).
In vitro endothelial cell morphogenesis assay (capillary
morphogenesis)
Human aortic endothelial cell (HAEC) differentiation into
capillary-like structures was examined using a two dimensional
Matrigel-based assay as previously described [18]. Initially, 200 ml
of ice cold growth factor reduced-Matrigel (Becton-Dickson
Labware, Bedford, MA, USA) was placed into each well of a
Figure 4. Histology of MDA-MB-231 xenografts. Tumors dissected from animals were sectioned and stained with (A) H&E, and (B) mitotic
figures (arrowheads), and (C) apoptotic bodies (arrows) evaluated as described in Materials and Methods.
doi:10.1371/journal.pone.0034283.g004
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16 hours in MEBM media supplemented with EGMH-2 MV
SingleQuots kit. HAECs differentiated into capillary-like struc-
tures within 16 hours of incubation at 37uC. After 16 hours of
Figure 5. Expression of CD31 and VEGF in tumors. The expression of (A) CD31, and (B) VEGF were quantified as described in Materials and
Methods. Data are mean 6 SD (n=6–10), * significantly different from control (p,0.05) by ANOVA.
doi:10.1371/journal.pone.0034283.g005
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inverted Olympus CK40 microscope as previously described [18].
Quantification of the capillary-like structures was performed by
counting the number of nodes/field, where node is defined as an
intersection of at least three cells. Each sample was assayed in
triplicate and repeated at least three times.
Human breast cancer xenograft experiments
Female nude immunodeficient mice (nu/nu), 6 weeks old, were
purchased from Harlan (Indianapolis, IN, USA) and housed in
accordance with protocol approved by the Institutional Labora-
tory Animal Care and Use Committee of the Methodist Research
Institute. On day 0, human breast cancer MDA-MB-231 cells
(1610
6) suspended in 200 mL of DMEM medium were inoculated
subcutaneously (s.c.) in the right flank of each mouse. Seven days
after inoculation, mice were randomly divided into three groups
(n=10) and treated 3 times per week with 100 ml intraperitoneal
(i.p.) injection of vehicle (control) or NAHA (10 mg/kg and
50 mg/kg). Tumor sizes were measured three times a week using
calipers and their volumes were calculated using a standard
formula: tumor volume (mm
3)=(L 6W
2)61/2, where L is the
length and W is the width of the tumor. The animals were
sacrificed after 32 days. Body weight was measured three times
weekly. The protocol for animal experiments was approved by the
Animal Research Committee at the Methodist Hospital (protocol
number 2008-33) according to the NIH guidelines for the Care
and Use of Laboratory Animals.
Histology and Immunohistochemistry
Tumors were harvested, fixed in 10% neutral buffered formalin
at 4uC for 24 hours followed tissue processing overnight, and then
embedded in paraffin. Five-micrometer sections were stained for
routine H&E. The slides were viewed under a Leica microscope
(Leica Instruments, Melville, NY, USA) and the number of cells in
the viable tumor cell area was quantitated by counting both
apoptotic bodies and mitotic figures in four 206fields of view for
n=10 tumors per group. Rat anti-mouse CD31 monoclonal
antibody (clone SZ31) from Dianova (Hamburg, Germany) and
anti-VEGF antibody were utilized using standard automated
immunohistochemical techniques on the DAKO Autostainer and
3,39-diaminobenzadine as chromagen. For the CD31 positive
staining endothelial cells in small vessels, the small capillaries and
small vessels were counted in one 166 field. The CD31 and
VEGF positive cells were quantified by Image J (National
Institutes of Health, Bethesda, MD, USA). Three fields were
counted and averaged. The large necrotic areas in the xenograft
were excluded from analysis and only viable tumor areas were
used. The area captured averaged about 15 to 25% of the whole
cross sectional area of the tumor. For the immunohistochemical
quantification QC, three randomly selected images (166 power
fields) each (total area, 7.3 mm
2) from the tumor periphery were
analyzed in each tumor per group. Tumor periphery indicates a
region less than one field of view from the tumor edge at 6200
magnification (,1,360 microns), and tumor core indicates areas
.1,360 microns from the tumor edge.
Statistical analysis
Data are expressed as the mean 6 standard deviation (SD).
Statistical comparison between groups of data was carried out
using ANOVA. P,0.05 was considered to be significant.
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